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ABSTRACT
Background: GEMINI trials demonstrated the therapeutic efficacy of vedolizumab (VDZ) in Crohn’s
disease (CD) and ulcerative colitis (UC).
Research design and methods: Aim of this study was to determine the real-life effectiveness of VDZ
on endoscopic healing in the Hungarian nationwide cohort of inflammatory bowel disease (IBD)
patients based on the changes on clinical and endoscopic scores. Every adult IBD patient in the country
(121 UC and 83 CD) who completed the short-term VDZ therapy was enrolled, of which 72 UC and
52 CD patients could complete the long-term therapy.
Results: The rates of endoscopic healing were substantially higher in UC compared with CD patients
during the short- and long-term therapy (52.9% vs. 21.7%, p < 0.0001, and 51.4% vs. 21.2%, p = 0.015,
respectively). In CD, the rate of endoscopic healing was lower at week 14 compared with week 22
(14.5% vs. 37.0%, p = 0.026). Prior anti-TNF-α therapy (88.73%) was not associated with a significant
decrease in therapeutic response. The average disease duration was significantly lower in CD patients
achieving endoscopic healing at week 52 (11.75 vs. 5.27 years, p = 0.007).
Conclusions: VDZ therapy is an effective therapeutic option in anti-TNF-α refractory IBD. However, the
endoscopic healing rate was substantially lower and showed a significant delay in CD compared with
UC.
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1. Introduction
Gut-specific vedolizumab (VDZ) is a fully humanized monoclo-
nal antibody that specifically blocks α4β7 integrin, inhibiting
adhesion and migration of leukocytes into the damaged
intestinal mucosa. Previous randomized controlled trials
demonstrated that VDZ has comparable therapeutic efficacy
with tumor necrosis factor-α (TNF-α), blockers infliximab (IFX),
and adalimumab (ADA) in both Crohn’s disease (CD) and
ulcerative colitis (UC) but the only head-to-head comparison
was made in the VARSITY trial [1–5]. In this trial, vedolizumab
was superior to adalimumab in terms of achievement of clin-
ical remission and endoscopic improvement in patients with
moderately to severely active ulcerative colitis. LOVE-CD study
verified that endoscopic remission (SES-CD score <4) was
achievable in one-third of CD patients by week 52; in addition,
the rate of histologic remission by week 26 was 64% [6].
Nonetheless, in most countries, VDZ is frequently used
as second-line therapy in patients with anti-TNF-α refractory
disease.
In Hungary, VDZ has become an alternative option in the
management of moderate and severe IBD since 2016, but the
high treatment costs are currently limiting its availability. By
2019, all newly prescribed VDZ had to be based on an indivi-
dualized treatment decision and approved by the steering
committee of five Hungarian IBD-specialists. Because of this,
only patients with long-standing disease showing inadequate
response to conventional anti-TNF-α and/or immunosuppres-
sant therapies could receive VDZ treatment. Only patients with
relevant comorbidities (past medical history of cancer or
tuberculosis, severe heart failure, chronic hepatitis B or
C viral infection, etc.) and hence not candidates for other
therapeutic options were eligible for VDZ treatment.
Although several studies assessing VDZ effectiveness in real-
life setting have been published, fewer data on its effect on
endoscopic healing is available. Therefore, the aim of this
observational study was to assess the effectiveness of short-
and long-term VDZ treatment on IBD endoscopic healing in
real-life setting.
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2. Patients and methods
2.1. Patient enrollment, study protocol
This was a noninterventional, observational, multicenter
cohort study using prospectively collected clinical records of
all adult IBD patients in Hungary with moderate and severe
disease activity who received and completed short-term VDZ
therapy between July 2016 and December 2018. Concomitant
immunosuppressant and corticosteroid treatment were
allowed at inclusion, but combination therapy with another
biological agent was not permitted. All enrolled patients
received 300 mg VDZ as an intravenous infusion at 0, 2, and
6 weeks followed by an every-8-week maintenance regimen.
Study protocol was approved by the Regional and
Institutional Human Medical Biological Research Ethics
Committee of the University of Szeged (clinical trial registra-
tion number: 99/2017-SZTE). The study was carried out under
the Declaration of Helsinki.
2.2. Response evaluation
The therapeutic response was assessed based on changes in
clinical (Crohn’s Disease Activity Index [CDAI], Mayo score) and
endoscopic (Simple Endoscopic Score for Crohn’s Disease
[SES-CD], endoscopic Mayo score) activity scores. Clinical
response was defined as a >3-point decrease in total Mayo
score or a >100-point decrease in CDAI score from baseline.
Remission was defined as Mayo score ≤2, with no individual
subscores >1, or as CDAI score ≤150. Colonoscopy for endo-
scopic activity evaluation was performed immediately before
therapeutic request submission and control examinations
before initiation of maintenance and second-year therapies.
Endoscopic healing was defined as Mayo endoscopic subscore
≤1 or SES-CD score ≤4.
The primary study endpoint was endoscopic healing rate
by the end of short- and long-term VDZ treatment, based on
endoscopic findings and scores. After September 2017, the
timing of control examinations was changed due to modified
Hungarian health insurance VDZ funding, which required
a change in the definition of short-term efficacy. Before
September 2017, it was defined as a therapeutic response
to VDZ treatment at week 14. After this date, short-term
efficacy assessment has been performed following the third
VDZ infusion in UC and the fifth infusion in CD. Long-term
therapeutic response was evaluated after the first year of
treatment, at week 52. The co-primary study endpoint was
determination of short- and long-term therapeutic response
to VDZ. Patients’ clinical data were collected using the
Hungarian IBD-specialist committee database, which is
based on therapeutic request forms. Information about sus-
pended treatments was provided by the physicians of IBD
patients.
The secondary study endpoint was identification of poten-
tial predictors of therapeutic response and assessment of the
impact of concomitant medication use on short- and long-
term outcomes of VDZ treatment. Correlations between VDZ
trough level (TL) changes, laboratory parameters (hematocrit
[HCT], hemoglobin [HGB], C-reactive protein [CRP], white
blood cell [WBC], platelet count [PLT]), and therapeutic
response during follow-up were further examined.
Serum VDZ and antibody levels were evaluated during
maintenance therapy. For that purpose, blood samples were
collected immediately before regular VDZ infusion (TL) admin-
istration. Serum samples were tested by quantitative enzyme-
linked immunosorbent assay (ELISA) with LISA-TRACKER Duo
Vedolizumab (Theradiag, France). VDZ-TLs and anti-VDZ anti-
bodies are quantified using a specific biotinylated antibody
directed against the idiotype of VDZ, and a biotinalyted VDZ
against anti-VDZ antibody. The assay range for VDZ-TL is
between 2 μg/mL and 60 μg/mL, and anti-VDZ is between
35 ng/mL and 500 ng/mL.
2.3. Statistical analysis
Statistical tests were performed using R statistical software ver-
sion 3.6.0 (R Foundation) and SPSS software version 24 (SPSS Inc.,
Chicago, Illinois, USA), with p < 0.05 considered statistically sig-
nificant. Chi-squared and Fisher’s exact tests were applied to
compare categorical variables, and t-test was used to compare
continuous variables between groups. Depending on the results
of Levene’s test for homogeneity of variances, one-way analysis
of variance and Tukey’s honest significant difference or Dunnett’s
T3 post hoc test were used to compare laboratory parameters.
Paired t-test was applied to evaluate mean changes in clinical
and endoscopic activity indices during short and long-term
treatment. Missing data were imputed using the last observation
carried forward approach. Q–Q plot (quantile–quantile plot) and
density plot were used for checking normality of data visually.
Disease duration cutoff was determined by receiver operating
characteristic (ROC) curve analysis, using endoscopic healing as
a classification variable to calculate the area under the ROC
curve.
3. Results
3.1. Patient baseline characteristics
A total of 348 VDZ therapeutic application requests were
submitted between July 2016 and December 2018 in
Hungary, from which 244 (70.11%) were approved (Figure 1).
VDZ treatment eventually did not start in 15 cases because of
earlier therapeutic switching or surgical interventions required
due to severe disease activity. Twenty-one patients with
ongoing short-term therapy and four pediatric IBD patients
were excluded from the study. All 204 enrolled cases (121 UC
and 83 CD) had completed short-term VDZ treatment.
Although in 124 cases (60.78%; 72 UC and 52 CD) the 1-year
treatment could potentially be finished during the study per-
iod, maintenance treatment was not approved in 32 cases
(25.8%) due to primary nonresponse. One patient moved to
abroad, therefore VDZ therapy was interrupted, and in one
case, colorectal cancer was found by control endoscopy at
week 14. Ninety patients (58 UC and 32 CD) received VDZ
maintenance therapy. Table 1 summarizes the clinical and
demographical data of enrolled IBD patients. The average
disease duration was 10.04 ± 7.40 years, being less than
3 years only in 26 cases (12.75%). A total of 181 patients
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(88.73%) received previous anti-TNF-α therapy (80.88% IFX;
71.08% ADA; 1.47% golimumab). A switch to another anti-
TNF-α or to VDZ was required in 43 cases of primary nonre-
sponse and in 192 cases of response loss. Adverse events were
observed in 67 cases, the most frequent being infusion reac-
tions (N = 42; 20.59%), infections (N = 5; 2.45%), reactivation of
tuberculosis (N = 3; 1.47%), and hematological effects (N = 3;
1.47%). Only 23 patients (11.27%) were naïve to anti-TNF-α
inhibitors: in 7 cases, past medical history of malignancy con-
traindicated the use of these agents; in 7 and 4 cases, severe
comorbidities and high risk for infections (cystic fibrosis, renal
transplantation), respectively, required the use of gut-selective
biological agents; and 5 patients were young (<20 years old)
with newly diagnosed, severely active IBD.
3.2. Endoscopic healing
Significant differences in endoscopic healing rates were
observed between UC and CD subgroups by the end of short-
and long-term therapy (52.9% vs. 21.7%, p < 0.0001, and 51.4%
vs. 21.2%, p = 0.015, respectively). Clinical response and mucosal
regeneration during VDZ treatment are very fast in UC, which
was supported by the fact that the proportion of partial or
complete endoscopic healing detected by control colonoscopy
after the third (week 6) and fourth (week 14) infusions did not
substantially differ (44.19% vs. 57.69%, p = 0.185). In CD,
although lower rates of endoscopic healing were not observed,
healing rates were significantly delayed compared with UC, with
substantial endoscopic healing differences detected byweeks 14
and 22 (14.5% vs. 37.0%, p = 0.026). At the end of short-term
Figure 1. Flowchart of patients’ enrollment.
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therapy, none of the examined clinical or demographical data
predicted therapy outcomes on endoscopic healing; however, in
CD, the average disease duration was significantly lower in
patients achieving complete endoscopic remission compared
with patients not achieving endoscopic healing (11.75 vs.
5.27 years, p = 0.007). (Figure 2) (Table 2)
Average endoscopic activity index values significantly
dropped during the study period compared with baseline: in
UC, the mean eMayo score decreased from 2.80 to 1.41 by the
end of short-term treatment and to 1.40 at week 52
(p < 0.0001); in CD, mean SES-CD decreased from 20.89 (95%
CI, 16.52–25.26) to 13.48 (95% CI, 9.09–17.86) at weeks 14–22
in the short-term subgroup and from 19.49 (95% CI, 17.07–-
21.91) to 12.80 (95% CI, 10.11–15.50) at week 52 (p < 0.0001).
3.3. Therapeutic response
By the end of short-term VDZ therapy, the rate of clinical
response was substantially higher in the UC compared with CD
subgroup (84.30% vs. 61.45%; p < 0.0001), but this difference lost
by week 52 (65.28% vs. 42.31%; p = 0.307). No significant differ-
ences were found in the proportion of clinical remission and
steroid-free remission between UC and CD subgroups by the
end of short-term treatment (49.59% vs. 51.81%, p = 0.777, and
27.27% vs. 37.35%, p = 0.167, respectively) or at 1-year follow-up
(47.22% vs. 32.69%, p = 0.825, and 44.44% vs. 30.77%, p = 0.826,
respectively) (Figure 3). Modification in the definition of short-
term efficacy did not result in a substantial change in VDZ
clinical response rate, either in UC (at week 6 [N = 43] vs. at
week 14 [N = 78]) or CD (at week 14 [N = 56] vs. at week 22
[N = 27]) subgroup (83.72% vs. 84.62%, p = 1.000, and 58.93% vs.
66.67%, p = 0.6615, respectively). By the end of short-term VDZ
treatment, steroids could be tapered and ceased in 52.46% of
patients receiving systemic corticosteroids at inclusion, with this
rate increasing to 68.13% at 1-year follow-up. Mean activity
scores significantly decreased during follow-up compared with
baseline (Figure 4). Neither disease duration and phenotype nor
concomitant medication (azathioprine, cyclosporine A, metho-
trexate, or systemic corticosteroid) uses influenced short- and
Table 1. Clinical and demographic data of enrolled inflammatory bowel disease
patients.
CLINICAL AND DEMOGRAPHICAL PATIENT DATA
SHORT-TERM TREATMENT
(N = 204)
LONG-TERM TREATMENT
(N = 124)
Female/male (Nr) 94/110 55/69
UC/CD (Nr) 121/83 72/52
UC pancolitis 83 (68.60%) 55 (76.39%)
left-sided colitis 32 (25.45%) 13 (18.56%)
proctosigmoid 6 (4.96%) 4 (5.55%)
CD ileal (L1) 5 (6.02%) 3 (5.77%)
colonic (L2) 26 (31.33%) 17 (32.69%)
ileocolonic (L3) 52 (62.65%) 32 (61.54%)
inflammatory (B1) 50 (60.24%) 29 (55.77%)
stricturing (B2) 22 (26.5%) 17 (32.69%)
penetrating (B3) 11 (13.25%) 6 (11.54%)
perianal (p) 7 (8.43%) 4 (7.69%)
Age at diagnosis (years) 39.59 ± 15.87 39.91 ± 15.93
Disease duration (years) 10.04 ± 7.40 10.72 ± 7.68
Primary sclerosing cholangitis 11 (5.39%) 9 (7.26%)
Extraintestinal involvement 57 (27.94%) 32 (25.81%)
Previous anti-TNF-α therapy 181 (88.73%) 113 (91.13%)
infliximab 36 (17.65%) 19 (15.32%)
adalimumab 16 (7.84%) 10 (8.06%)
both anti-TNF-α 129 (63.24%) 84 (67.74%)
Complication during previous
anti-TNF-α therapy 67 (32.84%) 39 (31.45%)
allergic reaction 42 (20.59%) 21 (16.94%)
infection 15 (7.35%) 10 (8.06%)
other 10 (4.90%) 8 (6.45%)
Previous surgery (Nr; %) 36 (17.65%) 22 (17.74%)
Concomitant therapy (Nr; %)
azathioprine 70 (34.31%) 48 (38.71%)
systemic steroid 156 (76.47%) 91 (73.39%)
5-aminosalycilate 158 (77.45%) 86 (69.35%)
methotrexate 9 (4.41%) 4 (3.22%)
cyclosporine 16 (7.84%) 10 (8.06%)
(UC, ulcerative colitis; CD, Crohn’s disease; TNF, tumor necrosis factor).
Figure 2. (a) This is a half violin with each observation records displayed in dots. In Crohn’s disease, the average disease duration was significantly higher in patients
with complete endoscopic remission compared with patients without endoscopic healing during long-term vedolizumab therapy (11.75 vs. 5.27, p < 0.007). (b) ROC
curve shows 83.9% of patients correctly attributed to the endoscopic healing group using 6.5-year disease duration cutoff.
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long-term VDZ outcomes, and previous anti-TNF-α treatment
was not associated with higher risk of primary nonresponse.
Only one patient had adverse, mild allergy-like reaction
during the second VDZ infusion which required systemic cor-
ticosteroid and antihistamine administration before the fol-
lowing three VDZ infusions. VDZ therapy was suspended
after the short-term treatment due to primary non-response.
In one case, cytomegalovirus infection was observed during
induction therapy, but presumably this infection had been
acquired before initiation of VDZ.
3.4. Laboratory parameters and VDZ trough levels
Serum CRP levels, PLT counts, and HGB concentrations were
checked before the initiation of long-term therapy, and their
role in clinical response was investigated. CRP was significantly
higher in short-term VDZ responders compared with primary
nonresponders. In CD, clinical response was associated with
a significant change in average PLT values, but this decrease
was not detected in UC. HGB levels were independent of
clinical response. (Figure 5)
VDZ antibodies were not detected in any of the 54 exam-
ined (47 nonresponders and 7 responders) cases. VDZ-TL mea-
surements were performed in 47 cases of during maintenance
therapy (41 responders and 6 nonresponders). No correlation
was found between VDZ-TLs and either clinical response or
endoscopic healing. Mean VDZ-TL values were higher in non-
responders compared with responders (35.32 μg/mL vs
21.73 μg/mL) and in patients not achieving compared with
those achieving endoscopic healing (25.95 μg/mL vs.
20.39 μg/mL). Table 3 shows clinical response and endoscopic
healing according to 15 μg/mL VDZ-TL cutoff.
Table 2. Assessment of endoscopic healing predictors during short- and long-term vedolizumab therapy (L, location of disease; L1, ileal; L2, colonic; L3, ileocolonic;
B, behavior of disease; B1, inflammatory; B2, stricturing; B3, penetrating; 5-ASA, 5-amino-salicilate; anti-TNF-α, anti-tumor necrosis factor-α).
PREDICTORS OF ENDOSCOPIC HEALING
CROHN’S DISEASE ULCERATIVE COLITIS
SHORT-TERM LONG-TERM SHORT-TERM LONG-TERM
Responder p-value Responder p-value Responder p-value Responder p-value
Male/female 20.0% vs. 23.4% 0.464 41.2% vs. 26.7% 0.472 49.2% vs. 56.7% 0.260 55.9% vs. 72.0% 0.278
Age at diagnosis (year) 35.41 vs. 39.89 0.292 34.52 vs. 33.55 0.871 43.18 vs. 40.76 0.398 40.62 vs. 42.86 0.573
Disease duration (year) 11.35 vs. 8.50 0.148 11.75 vs. 5.27 0.007 9.12 vs. 10.06 0.492 9.86 vs. 10.95 0.602
Disease phenotype B1: 28.0%
B2: 14.3%
B3: 9.1%
L1: 60.0%
L2: 20.0%
L3: 19.6%
0.243
0.111
B1: 33.3%
B2: 33.4%
B3: 33.3%
L1: 100%
L2: 44.4%
L3: 21.1%
0.986
0.025
Proctosigmoid:
66.7%
Left-sided:
53.1%
Pancolitis:
51.8%
0.496
Proctosigmoid:
50.0%
Left-sided:
70.0%
Pancolitis:
62.2%
0.776
Prior surgery 22.9% vs. 20.6% 0.802 35.0% vs. 33.3% 0.923 NA NA
Concomitant azathioprine 23.9% vs. 19.4% 0.789 26.7% vs. 31.8% 0.472 53.4% vs. 50.0% 0.853 59.5% vs. 70.6% 0.556
Concomitant
systemic steroid
21.7% vs. 22.0% 0.614 40.0% vs. 31.8% 0.703 43.5% vs. 55.1% 0.220 66.7% vs. 61.7% 0.751
Concomitant
cyclosporine
22.4% vs. 16.7% 0.745 34.5% vs. 33.3% 0.968 54.1% vs. 40.0% 0.514 63.6% vs. 50.0% 0.624
Concomitant
methotrexate
22.4% vs. 16.7% 0.745 33.3% vs. 50.0% 0.631 52.5% vs. 66.7% 0.628 NA
Concomitant
5-ASA
11.1% vs. 27.3% 0.155 33.3% vs. 35.3% 0.907 50.0% vs. 53.4% 0.804 54.5% vs. 64.6% 0.731
Prior anti-TNF-α 20.0% vs. 22.2% 0.874 50.0% vs. 32.1% 0.593 53.8% vs. 52.8% 0.942 75.0% vs. 61.8% 0.599
Figure 3. Short- and long-term efficacy of vedolizumab therapy on clinical response, remission, steroid-free remission, and endoscopic healing (UC, ulcerative colitis;
CD, Crohn’s disease).
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Figure 4. (a–b) Mean Crohn’s Disease Activity Index (CDAI: in short-term subgroups 303.58 [95% CI, 289.59–317.57] vs. 157.66 [95% CI, 145.80–189.52] and in long-
term subgroup CDAI: 309.67 [95% CI, 294.83–324.52] vs. 172.65 [95% CI, 145.32–199.99] vs. 184.08 [95% CI, 154.61–213.54]) and Mayo score (in short-term
subgroup 9.74 [95% CI, 9.48–9.99] vs. 4.33 [95% CI, 3.82–4.84] and in long-term subgroups 9.60 [95% CI, 9.24–9.95] vs. 4.38 [95% CI, 3.51–4.80] vs. 4.38 [95% CI,
3.61–5.14]) significantly decreased during short- and long-term vedolizumab therapy compared with baseline. (c) Mean Simple Endoscopic Score for Crohn’s Disease
(SES-CD) significantly decreased from 20.89 (95% CI, 16.52–25.26) to 13.48 (95% CI, 9.09–17.86) in short-term subgroup and from 19.49 (95% CI, 17.07–21.91) to
12.04 (95% CI, 9.54–14.54) by the end of short-term and to 12.80 (95% CI, 10.11–15.50) by the end of long-term vedolizumab therapy in the long-term subgroup. (d)
Percentage component bar chart shows the distribution of different endoscopic Mayo (eMayo) scores in the study population at baseline and at the end of short-
and long-term vedolizumab treatment.
Figure 5. Serum C-reactive protein (CRP) decreases during short-term vedolizumab (VDZ) therapy was significantly higher in clinical responders compared with
nonresponders. However, correlation between platelet count (PLT) and clinical response was only observed in Crohn’s disease (CD). Hemoglobin levels did not
significantly differ between responders and nonresponders by the end of short-term treatment. (UC, ulcerative colitis).
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4. Discussion
The present multicenter cohort study assessed the effective-
ness of VDZ therapy on endoscopic healing in moderate and
severe active IBD. The most important advantage of this
investigation is that it involved all patients receiving VDZ
treatment in the entire country. In addition, VDZ special reg-
ulations and health insurance funding—which required
confirmation of therapeutic response by endoscopic
examination—allowed evaluation, not only of clinical response
but also of endoscopic healing in real-life setting. The strict,
two-phase VDZ approval process can be considered as both
an advantage and disadvantage of the study, as it resulted in
the selection of a particularly difficult-to-treat population with
long-standing anti-TNF-α and/or immunosuppressant resistant
disease. At the same time, our results cannot be generalized,
and might not be applied to other countries, where VDZ is
available as first-line treatment and can also be applied in
patients who have better prognostic factors.
The results of this study suggest that both short-term and
1-year long-term maintenance VDZ therapy is an effective and
safe therapeutic option in this difficult-to-treat population.
However, significant differences were observed between UC
and CD subgroups in terms of therapeutic effectiveness.
Lower and delayed therapeutic response was achieved in CD
compared with UC, which was evident also in the lower endo-
scopic healing rate. This observation correlates with the results
of most previously published studies [5,7]. The GEMINI 1 and 2
randomized controlled trials found substantially greater
response and remission rates in UC compared with CD, both
at week 6 (47.1% and 16.9% vs. 31.4% and 14.5%) and week 52
(56.6% and 41.8% vs. 39.0% and 43.5%) [1,3]. In addition, Sands
et al. found that VDZ was not more effective than placebo on
clinical remission at week 6 among patients with TNF antago-
nist-refractory CD. In this case, therapeutic benefits were
detectable only after week 10 [8]. The reason for the therapeutic
response difference between CD and UC patients is still not
clearly understood, but it may be presumably related with the
transmural nature of CD and mechanism of action of VDZ. VDZ
is a gut-specific antibody against α4β7 integrin, which is
expressed on the surface of mononuclear cells such as
T-lymphocytes. This integrin binds to mucosal addressing cell
adhesion molecule-1 (MAdCAM.1) expressed by the endothelial
cells in venules within the gastrointestinal tract and on high
endothelial venules in gut-associated lymphoid tissue, includ-
ing Peyer’s patches and mesenteric lymph nodes [9,10]. Th1-
cells promote the proliferation of mononuclear phagocytes,
neutrophil granulocytes, and the maturation of M1 proinflam-
matory macrophages and natural killer (NK) cells, which leads to
colonic epithelial damage in IBD [11]. VDZ by blocking the α4β7
integrin inhibits adhesion and migration of T-cells into the
damaged intestinal mucosa. Some authors assume that VDZ
may be less effective in cases of deep mural inflammation due
to mechanism of action [12]. In contrast with this hypothesis,
some recently published studies found no difference in VDZ
effectiveness among UC and CD patients [13,14].
In our UC patient cohort, endoscopic remission was achiev-
able in every second case during short-term and every third
case during long-term treatment; however, in cases of CD, the
rate of endoscopic remission was significantly lower com-
pared with UC, about 20% at both checkpoints. This is partly
similar to the results of a recently published Belgian real-life,
retrospective observational study in which 56.1% of UC and
39.1% of CD patients achieved the endoscopic endpoint [15].
In most clinical trials, the endoscopic remission rate in CD was
almost twice as high as our results that can be explained by
the fact that only difficult-to-treat patients could receive vedo-
lizumab in our cohort who showed primary non-response or
loss-of-response to at least one biological agent and/or immu-
nomodulator [6,15–17]. The post hoc analysis of GEMINI 1 and
2 trials suggested that previous medication, especially prior
biological therapy, substantially influenced VDZ effectiveness,
with VDZ appearing to have greater benefits in anti-TNF-α-
naïve IBD patients when effectiveness and health-related
quality of life indicators were assessed [2,18,19].
Nonetheless, among patients who responded to VDZ induc-
tion therapy at week 6, a high percentage remained on main-
tenance therapy and achieved remission by week 104
regardless of prior anti-TNF-α exposure, with no considerable
differences between UC and CD in this regard (88% and 83%,
respectively) [20,21]. Similar results have been recently
reported by Swedish (SWIBREG), Finnish (FINVEDO),
Japanese, British (REVIVE), and Scottish nationwide cohort
studies, among others [13,22–25]. In the Hungarian cohort,
prior anti-TNF-α exposure was not associated with lower clin-
ical response rates by the end of short-term VDZ therapy;
however, the anti-TNF-α-naïve sample size may have been
too small to detect a statistically significant difference. In
addition, concomitant azathioprine, cyclosporine, and sys-
temic corticosteroid therapy were not associated with an
increased benefit, in contrast with results from GEMINI 2 and
4 and other studies [26–29].
The highest effectiveness of VDZ therapy can be achieved
when it is used as a first-line agent shortly after the onset of
disease in patients who failed conventional therapies, such as
immunosuppressants, 5-aminosalicylates, cyclosporine, and
corticosteroids [30–32]. In these cases, the therapeutic effect
of VDZ and other biologics is almost the same in UC and CD,
and VDZ fistula closure rate is close to that of IFX and ADA
[33]. Post hoc analysis of GEMINI 2 detected 28% of fistula
closure rate at week 14 and 33% at week 52 with VDZ treat-
ment [34]. However, a retrospective study by Yamada et al.
found a higher postoperative endoscopic recurrence in CD
with VDZ than with anti-TNF-α agents [35]. In this study, the
low number of perianal CD did not allow assessment of VDZ
effectiveness on fistula healing. However, no differences were
found in clinical response and mucosal healing rates between
anti-TNF-α-refractory and -naïve IBD patients.
Table 3. Correlation between therapeutic response and vedolizumab trough
(VDZ-TL) levels using 15 μg/mL cutoff value.
<15 μg/mL >15 μg/mL
Clinical response NO 2 (33.33%) 4 (66.67%)
YES 17 (41.46%) 24 (58.53%)
Endoscopic healing NO 11 (42.31%) 15 (57.69%)
YES 8 (38.10%) 13 (61.90%)
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Contradictory data about the clinical relevance of VDZ-TL
and VDZ-directed antibody measurements exist. Pouillon
et al., Yacoub et al., and Hanžel et al. found that histological
healing is associated with higher VDZ-TL during maintenance
therapy in UC, and the 18–25 μg/mL TL threshold proved to
be optimal in predicting histological healing [36–38]. A meta-
analysis published in 2019, which assessed the results of five
cohort studies, concluded that VDZ concentration >20 μg/mL
at week 6, and >12 μg/mL during maintenance may be asso-
ciated with better outcomes [39]. In contrast, the study by Al-
Bawardy et al. did not detect an association between VDZ-TL
and mucosal healing [40]. GEMINI long-term safety study
found that antibodies against VDZ developed in only 5% of
patients, and there was no relationship between immunogeni-
city and safety [41]. In this study, VDZ-TL showed no correla-
tion with clinical response or mucosal healing, and antibody
formation against VDZ was not detectable in any case.
The most important limitation of this study is the fact that
it is a noninterventional, observational trial with open-label
design and no control groups. Enrolled patients were from
different institutions, and as such, some heterogeneity in clin-
ical response and endoscopic activity assessment may exist.
On the other hand, this also represents the real-life nature of
the study. Only therapeutic efficacy of VDZ on clinical activity
and endoscopic healing was determined, and the effect of
VDZ therapy for extraintestinal manifestations and perianal
activity of CD was not evaluated. The measurement of VDZ
trough levels and antibody against VDZ were available only in
two clinical centers, so they are not representative for the
whole study population. Therefore, it allowed only to assess
whether measurement of these parameters helped to deter-
mine the therapeutic response.
5. Conclusion
This study confirms that both short-term and first-year main-
tenance VDZ therapy is a safe and effective therapeutic option
in anti-TNF-α failing or intolerant IBD patients with moderate
or severe disease activity, with no significant differences
observed between UC and CD subgroups. Endoscopic healing
was achieved in half of UC and only a fifth of CD patients by
the end of the two evaluation time points in this difficult-to-
treat population. As disease duration is an important predic-
tive factor of endoscopic healing in CD, the optimal effect of
VDZ in this population may be achieved with early therapy,
starting less than 5 years after disease diagnosis. In addition,
due to delayed response, evaluation of VDZ therapeutic effect
is not yet possible after induction therapy. VDZ-TL measure-
ment did not help to predict therapeutic response and endo-
scopic healing.
Author contributions
Conception and design of the study, supervision of patient selection: Bor
R, Molnár T, Miheller P, Vincze Á, Szamosi T, Palatka K. Acquisition of data:
Bor R, Fábián A, Szepes Z, Farkas K, Rutka M, Szántó K, Zsigmond F, Bálint
A, Nagy F, Milassin Á, Tóth T, Zsigmond F, Bajor J, Lakner L, Müllner K,
Papp M, Salamon Á, Horváth G, Sarang K, Schäfer E, Sarlós P.
Drafting of the manuscript: Bor R, Fábián A, Szepes Z, Molnár
T. Critical revision for important intellectual content: Szepes Z,
Vincze Á, Miheller P, Palatka K, Molnár T. Analysis and interpretation
of data: Matuz M, Bor R. All authors have approved the final draft
submitted.
Funding
This work was supported by the research grants of the National Research,
Development and Innovation Office [Grant ID: 119809, 125377 and
129266] and by the EFOP-3.6.2-16-2017-00006.
Declaration of interest
The authors have no other relevant affiliations or financial involvement
with any organization or entity with a financial interest in or financial
conflict with the subject matter or materials discussed in the manuscript
apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial relationships
or otherwise to disclose.
ORCID
Renáta Bor http://orcid.org/0000-0001-9393-5240
Anna Fábián http://orcid.org/0000-0002-0824-7476
Zoltán Szepes http://orcid.org/0000-0002-9466-8719
Klaudia Farkas http://orcid.org/0000-0003-0599-182X
Mariann Rutka http://orcid.org/0000-0003-2360-7836
Kata Szántó http://orcid.org/0000-0003-0749-5061
Anita Bálint http://orcid.org/0000-0002-3624-896X
Ágnes Milassin http://orcid.org/0000-0001-6902-8915
References
Papers of special note have been highlighted as either of interest (•) or of
considerable interest (••) to readers.
1. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induc-
tion and maintenance therapy for Crohn’s disease. N Engl J Med.
2013;369(8):711–721.
• First and largest randomized conrolled trial assessing efficacy
of vedolizumab therapy in cases of Crohn's Disease patients.
2. Feagan BG, Patel H, Colombel J-F, et al. Effects of vedolizumab on
health-related quality of life in patients with ulcerative colitis:
results from the randomised GEMINI 1 trial. Aliment Pharmacol
Ther. 2017;45(2):264–275.
• First and largest randomized controlled trial assessing efficacy
of vedolizumab therapy in cases of ulcerative colitis patients.
3. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction
and maintenance therapy for ulcerative colitis. N Engl J Med.
2013;369(8):699–710.
4. Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus
adalimumab for moderate-to-severe ulcerative colitis. N Engl
J Med. 2019;381(13):1215–1226.
5. Amiot A, Serrero M, Peyrin-Biroulet L, et al. One-year effectiveness
and safety of vedolizumab therapy for inflammatory bowel disease:
a prospective multicentre cohort study. Aliment Pharmacol Ther.
2017;46(3):310–321.
6. Löwenberg M, Vermeire S, Mostafavi N, et al. Vedolizumab induces
endoscopic and histologic remission in patients with Crohn’s dis-
ease. Gastroenterology. 2019;157(4):997–1006.e6.
•• This is the largest study which assessed separately the endo-
scopic healing and histologic healing during vedolizumab
therapy in patients with Crohn's disease.
7. Chaparro M, Garre A, Ricart E, et al. Short and long-term effective-
ness and safety of vedolizumab in inflammatory bowel disease:
212 R. BOR ET AL.
results from the ENEIDA registry. Aliment Pharmacol Ther. 2018;48
(8):839–851.
8. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab
induction therapy for patients with Crohn’s disease in whom tumor
necrosis factor antagonist treatment failed. Gastroenterology.
2014;147(3):618–627.e3.
9. McLean LP, Cross RK. Pharmacodynamic assessment of vedolizu-
mab for the treatment of ulcerative colitis. Expert Opin Drug Metab
Toxicol. 2016;12(7):833–842.
10. Rogler G. Mechanism of action of vedolizumab: do we really under-
stand it? Gut. 2019;68(1):4–5.
11. Zundler S, Neurath MF. Immunopathogenesis of inflammatory
bowel diseases: functional role of T cells and T cell homing. Clin
Exp Rheumatol. n.d.;33(4 Suppl 92):S19–28.
12. Lam MC, Bressler B. Vedolizumab for ulcerative colitis and Crohn’s
disease: results and implications of GEMINI studies.
Immunotherapy. 2014;6(9):963–971.
13. Eriksson C, Marsal J, Bergemalm D, et al. Long-term effectiveness of
vedolizumab in inflammatory bowel disease: a national study based
on the Swedish National Quality Registry for Inflammatory Bowel
Disease (SWIBREG). Scand J Gastroenterol. 2017;52(6–7):722–729.
14. Shelton E, Allegretti JR, Stevens B, et al. Efficacy of vedolizumab as
induction therapy in refractory IBD patients. Inflamm Bowel Dis.
2015;21(12):2879–2885.
15. Verstockt B, Mertens E, Dreesen E, et al. Influence of drug exposure
on vedolizumab-induced endoscopic remission in anti-TNF naïve
and anti-TNF exposed IBD patients. J Crohns Colitis. 2019;pii: jjz151.
DOI:10.1093/ecco-jcc/jjz151.
16. Kotze PG, Ma C, Almutairdi A, et al. Real-world clinical, endoscopic
and radiographic efficacy of vedolizumab for the treatment of
inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48
(6):626–637.
17. Arijs I, De Hertogh G, Lemmens B, et al. Effect of vedolizumab (anti-
α4β7-integrin) therapy on histological healing and mucosal gene
expression in patients with UC. Gut. 2018;67(1):43–52.
18. Feagan BG, Rubin DT, Danese S, et al. Efficacy of vedolizumab
induction and maintenance therapy in patients with ulcerative
colitis, regardless of prior exposure to tumor necrosis factor
antagonists. Clin Gastroenterol Hepatol. 2017;15(2):229–239.e5.
19. Sands BE, Sandborn WJ, Van Assche G, et al. Vedolizumab as
induction and maintenance therapy for Crohnʼs disease in patients
naïve to or who have failed tumor necrosis factor antagonist
therapy. Inflamm Bowel Dis. 2017;23(1):97–106.
20. Vermeire S, Loftus EV, Colombel J-F, et al. Long-term efficacy of
vedolizumab for Crohn’s disease. J Crohn’s Colitis. 2016;109(4):
jjw176.
21. Loftus EV, Colombel J-F, Feagan BG, et al. Long-term efficacy of
vedolizumab for ulcerative colitis. J Crohn’s Colitis. 2016;11(4):jjw177.
22. Ylisaukko-Oja T, Aaltonen J, Nuutinen H, et al. High treatment
persistence rate and significant endoscopic healing among
real-life patients treated with vedolizumab - a finnish nationwide
inflammatory bowel disease cohort study (FINVEDO). Scand
J Gastroenterol. 2018;53(2):158–167.
23. Motoya S, Watanabe K, Ogata H, et al. Vedolizumab in Japanese
patients with ulcerative colitis: a phase 3, randomized, double-blind,
placebo-controlled study. PLoS One. 2019;14(2):e0212989.
24. Cummings F, Gaya DR, Levison S, et al. A retrospective observa-
tional study of early experiences of vedolizumab treatment for
inflammatory bowel disease in the UK. Medicine (Baltimore).
2019;98(9):e14681.
25. Plevris N, Chuah CS, Allen RM, et al. Real-world effectiveness and
safety of vedolizumab for the treatment of inflammatory bowel
disease: the scottish vedolizumab cohort. J Crohn’s Colitis.
2019;13:1111–1120.
26. Allegretti JR, Barnes EL, Stevens B, et al. Predictors of clinical
response and remission at 1 year among a multicenter cohort of
patients with inflammatory bowel disease treated with
vedolizumab. Dig Dis Sci. 2017;62(6):1590–1596.
27. Szántó K, Molnár T, Farkas K. New promising combo therapy in
inflammatory bowel diseases refractory to anti-TNF agents: cyclos-
porine plus vedolizumab. J Crohn’s Colitis. 2018;12(5):629.
28. Sands BE, Van Assche G, et al. Vedolizumab in combination with
corticosteroids for induction therapy in Crohn’s disease: a post hoc
analysis of GEMINI 2 and 3. Inflamm Bowel Dis. 2019;25
(8):1375–1382.
29. Danese S, Sandborn WJ, Colombel J-F, et al. Endoscopic, radiologic,
and histologic healing with vedolizumab in patients with active
Crohn’s disease. Gastroenterology. 2019;157(4):1007–1018.e7.
30. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance inflix-
imab for Crohn’s disease: the ACCENT I randomised trial. Lancet.
2002;359(9317):1541–1549.
31. Colombel J, Sandborn WJ, Rutgeerts P, et al. Adalimumab for
maintenance of clinical response and remission in patients with
Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132
(1):52–65.
32. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces
and maintains clinical remission in patients with moderate-to-
severe ulcerative colitis. Gastroenterology. 2012;142(2):257–265.e3.
33. Sands BE, Blank MA, Diamond RH, et al. Maintenance infliximab
does not result in increased abscess development in fistulizing
Crohn’s disease: results from the ACCENT II study. Aliment
Pharmacol Ther. 2006;23(8):1127–1136.
34. Feagan BG, Schwartz D, Danese S, et al. Efficacy of vedolizumab in
fistulising Crohn’s disease: exploratory analyses of data from
GEMINI 2. J Crohns Colitis. 2018;12(5):621–626.
35. Yamada A, Komaki Y, Patel N, et al. The use of vedolizumab in
preventing postoperative recurrence of Crohn’s disease. Inflamm
Bowel Dis. 2018;24(3):502–509.
36. Pouillon L, Rousseau H, Busby-Venner H, et al. Vedolizumab trough
levels and histological healing during maintenance therapy in
ulcerative colitis. J Crohn’s Colitis. 2019;13(8):970–975.
37. Yacoub W, Williet N, Pouillon L, et al. Early vedolizumab trough
levels predict mucosal healing in inflammatory bowel disease:
a multicentre prospective observational study. Aliment Pharmacol
Ther. 2018;47(7):906–912.
38. Hanžel J, Sever N, Ferkolj I, et al. Early vedolizumab trough levels
predict combined endoscopic and clinical remission in inflamma-
tory bowel disease. United Eur Gastroenterol J. 2019;7(6):741–749.
39. Singh S, Dulai PS, Vande Casteele N, et al. Systematic review
with meta-analysis: association between vedolizumab trough
concentration and clinical outcomes in patients with inflamma-
tory bowel diseases. Aliment Pharmacol Ther. 2019;50
(8):848–857.
40. Al-Bawardy B, Ramos GP, Willrich MAV, et al. Vedolizumab drug
level correlation with clinical remission, biomarker normalization,
and mucosal healing in inflammatory bowel disease. Inflamm
Bowel Dis. 2019;25(3):580–586.
41. Wyant T, Yang L, Lirio R, et al. P441 long-term immunogenicity of
vedolizumab in ulcerative colitis and Crohn’s disease (GEMINI pro-
gramme). J Crohn’s Colitis. 2019;13(Supplement_1):S331–S331.
EXPERT OPINION ON BIOLOGICAL THERAPY 213
